نتایج جستجو برای: xeloda

تعداد نتایج: 238  

Journal: :International Journal of Medical Sciences 2008
Stefan Glück Edward F. McKenna Jr Melanie Royce

Combinations of capecitabine and a taxane are highly active in metastatic breast cancer, and synergy between capecitabine and docetaxel has also been demonstrated. Such combinations potentially would provide a promising non-anthracycline-based alternative for patients with early breast cancer. Non-anthracycline preoperative regimens are a particularly interesting proposition in human epidermal ...

Journal: :Oncology 2004
Michael J O'Connell

Adjuvant therapy with chemotherapy and/or radiation therapy in addition to surgery improves outcome for patients with high-risk carcinomas of the colon or rectum. For colon cancer, fluorouracil (5-FU) combined with leucovorin is a current standard of care that improves long-term survival. A recent European trial (MOSAIC) has documented significant improvement in 3-year disease-free survival whe...

2001
Eric Van Cutsem Chris Twelves Jim Cassidy David Allman Emilio Bajetta Michael Boyer Roland Bugat Mike Findlay Stefan Frings Michaela Jahn Joe McKendrick Bruno Osterwalder Gumersindo Perez-Manga Riccardo Rosso Philippe Rougier Wolff H. Schmiegel Jean-Francois Seitz Paul Thompson Jose Maria Vieitez

Purpose: To compare the efficacy and safety of orally administered capecitabine (Xeloda; Roche Laboratories, Inc, Nutley, NJ), a novel fluoropyrimidine carbamate designed to mimic continuous fluorouracil (5-FU) infusion but with preferential activation at the tumor site, with that of intravenous (IV) 5-FU plus leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer. Patien...

2016
Aiman Obed Anwar Jarrad Abdalla Bashir

BACKGROUND Associated Liver Partition and Portal vein ligation with Staged hepatectomy (ALPPS) leads to rapid hepatic hypertrophy and decreases incidence of post-hepatectomy liver failure in patients with a marginal future liver remnant. Various procedural ALPPS modifications were previously described. Here, we present the first case of a new ALPPS modification, carrying out a left hepatic tris...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 1998
J Cassidy L Dirix D Bissett B Reigner T Griffin D Allman B Osterwalder A T Van Oosterom

Capecitabine (Xeloda) is a novel rationally designed fluoropyrimidine carbamate. It passes through the intestinal mucosal membrane intact and is subsequently activated by a cascade of three enzymes resulting in preferential release of 5-fluorouracil (5-FU) at the tumor site. Preclinical studies indicated an enhancement of the therapeutic index when capecitabine was combined with leucovorin. Thi...

2017
Philip R Cohen

Capecitabine, an oral 5-fluorouracil prodrug, is currently used in the treatment of metastatic colorectal carcinoma and breast cancer. Fingerprints, also referred to as dermatoglyphics and characterized by the pattern of ridges and furrows on the fingertips, are used for identification by government agencies and personal electronic devices. Two women with breast cancer who were treated with cap...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 1999
C Twelves R Glynne-Jones J Cassidy J Schüller T Goggin B Roos L Banken M Utoh E Weidekamm B Reigner

Capecitabine (Xeloda) is a rationally designed oral, tumor-selective fluoropyrimidine carbamate aimed at preferential conversion to 5-fluorouracil (5-FU) within the tumor. Because capecitabine is extensively metabolized by the liver, it is important to establish whether liver dysfunction altered the pharmacokinetics of capecitabine and its metabolites. This was investigated in 14 cancer patient...

Journal: :Oncology reports 2013
Hideyuki Yasuno Mitsue Kurasawa Mieko Yanagisawa Yasuko Sato Naoki Harada Kazushige Mori

Molecular markers predicting sensitivity to anticancer drugs are important and useful not only for selecting potential responders but also for developing new combinations. In the present study, we analyzed the difference in the sensitivity of xenograft models to capecitabine (Xeloda®), 5'-deoxy-5-fluorouridine (5'-DFUR, doxifluridine, Furtulon®) a...

2004
Ro S. Eralp Bellibas Indra Patel Emmanuel Chamorey Bettyna Brivet Ernest D. Bush Catherine Kircher Stephane Nave Ludger Banken Nicole Renée Gérard Milano Antoine Lacassagne

Purpose: Ro 09-4889 was designed to enhance the anticancer efficacy of capecitabine (Xeloda) by generating a dihydropyrimidine dehydrogenase inhibitor (DPDi) 5-vinyluracil (5-VU) preferentially in tumor tissues. This study assessed the tolerance to Ro 09-4889 treatment, and related pharmacokinetic and pharmacodynamic data such as inhibition of DPD activity in peripheral blood mononuclear cells ...

2015
Anna Lisa Tedeschi Zohreh Eslami Evgenia Garoufalis Ramy R Saleh Atilla Omeroglu Gulbeyaz Altinel Maria Ait-Tihyaty Bertrand Jean-Claude Catalin Mihalcioiu

BACKGROUND The thymidine phosphorylase (TP) enzyme is expressed in higher levels in cancer tissue when compared with normal tissue. It is involved in the intratumoral activation of widely prescribed pyrimidine-derived antimetabolites such as 5'-deoxy-5-fluorouridine and capecitabine (Xeloda(®)). The purpose of this study was to determine the clinical correlation between TP expression in tumor t...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید